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Abstract
The aim of this chapter is to summarize the state-of-the-art knowledge of 
clinical staging in schizophrenia spectrum disorders. Clinical staging has been 
introduced to psychiatry in the past two decades. Its primary goal is to divide the 
course of the disorder into recognizable stages based on seriousness, development 
and symptom characteristics in order to better predict prognosis and to adopt the 
most appropriate treatment strategies. The first staging model was developed in 
1982. Since then several distinct concepts of clinical staging in psychiatry have 
emerged. To date, there is no clinical consensus regarding which staging model is 
the gold standard, nonetheless when merging them together an integrated staging 
concept arises. The integrated staging model of schizophrenia spectrum disorders 
is composed of four stages. The chapter will introduce the different staging models 
in a historical order as well as present the integrated staging model detailing the 
characteristics, timeline and dominating symptoms of each stage. Appropriate 
treatment strategies for the distinct stages will also be outlined.
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1. Introduction
Schizophrenia spectrum disorders (SSD) are a collection of psychotic disorders 
defined by abnormalities in one or more of the following symptom domains: 
hallucinations, delusions, disorganized thinking, catatonic behavior and negative 
symptoms [1]. The word ‘spectrum’ has been first added in the fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V) [1, 2], reflecting 
the notion that psychiatric disorders lie on a spectrum with no sharp boundaries 
between them [3, 4]. According to the DSM-V, SSD include schizophrenia, schizo-
phreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic 
disorder, psychotic disorders due to another medical condition or substance/medi-
cation, and unspecified or specified schizophrenia spectrum and other psychotic 
disorders [1]. The prevalence rate for SSD is estimated to be 7 per 1000 [5], with 
higher rates in men than in women [6]. Currently, there are over 21 million people 
who are affected by this condition [7]. Diagnosis is made along a spectrum of symp-
toms and severity via clinical interviews as no confirmatory and diagnostic labora-
tory nor radiological tests are available [2]. Although schizophrenia represents only 
about one third of the SSD cases [8], it is the most researched disorder out of all [9].
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Besides the internationally used diagnostic systems such as DSM or the 
International Classification of Diseases (ICD), there is another, complementary 
form of classifying psychiatric disorders called clinical staging [10]. First intro-
duced in cardiology and oncology [11], clinical staging is different from the conven-
tional diagnostic practices in a sense that it does not only define the extent of illness 
progression but also where a patient lies within the course of the disorder [10]. The 
basic assumptions of clinical staging are that (a) treatment in the early stages of 
the disorder is more efficient, (b) patients experience greater symptom severity in 
the later stages of the illness, and (c) the process of transferring to a later stage is 
connected with a typical clinical profile [12]. Although clinical staging as a model 
for classifying the development of disorders had been ignored in psychiatry in the 
past, several concepts have emerged in the past few decades [11]. The primary aim 
of clinical staging is promoting recovery in the early stages of psychiatric disorders 
as well as preventing progression to later stages [10]. Importantly, clinical stages 
of psychiatric disorders can be defined by many different aspects from symptom 
severity and persistence, through neurobiological changes, to the emotional 
processes that happen within the patient [10]. In this chapter, we aim to present, 
summarize and synthetize the clinical staging concepts of SSD through a system-
atic review.
2. Clinical staging concepts of schizophrenia spectrum disorders
The systematic review was conducted in November 2020 using the MEDLINE, 
EMBASE and Cochrane databases from 1999 with the following search terms: 
‘stage/staging’, combined using the Boolean ‘AND’ operator with ‘psychiatric 
disorder/schizophrenia/ psychosis/psychotic disorder’. Additionally, a manual 
search was also performed. Titles and abstracts were screened by one of the authors 
(Zs.D.) and relevant articles were independently assessed by two authors (A.B. and 
Zs.D.). English-language articles published in peer-reviewed journals describing 
complete staging models on SSD or psychiatric disorders, in general, were eligible to 
be included in the chapter (inclusion critera).
As a result of the systematic search, a total of 2045 articles were identified. After 
reviewing the abstracts to exclude those which clearly did not meet the above-
mentioned criteria, 27 articles remained. Of these, 9 articles were included in the 
final review.
2.1 The Hoffman staging concept
Although most reviews do not count the staging model of schizophrenia pro-
posed by Brian Hoffman in 1982, it can be considered to be the first attempt to 
divide the course of the disorder into recognizable stages [11, 13]. In his concept, 
Hoffman described the stages of schizophrenia based on the patient’s reaction to 
his or her symptoms, beginning with anxiety (stage 1) and ending with accep-
tance (stage 5) (Figure 1) [13]. In the early phase of schizophrenia, before the 
first episode, the patient goes through considerable changes in their behavior and 
experience disturbance in thinking which can result in fear and anxiety or even 
anger [13]. Then, during the first episode of schizophrenia, the patient experi-
ences a stage of denial (stage 2) where they no longer acknowledge that they have 
problem mainly due to excessive positive symptoms [13]. The third stage is about 
ambivalence, where the patients begin to have some insight into their disorder but 
might reject medication and go through multiple hospitalizations [13]. Before the 
final stage, acceptance (stage 5), there is a stage of depression (stage 4) where the 
3
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patient realizes the seriousness of the disorder [13]. During this stage it is important 
to monitor the patient to prevent suicide and alter the medication doses accordingly 
[13]. Although this staging concept is different from the others, it recognizes the 
importance of taking into account the patient’s emotional response to his or her 
symptoms and the progression of the disorder which is now considered vital in a 
modern, person-centered care [14].
2.2 The Fava & Kellner staging concept
The first staging model of schizophrenia is attributed to Fava and Kellner who 
proposed their concept in 1993 [11, 15]. According to their model, schizophrenia 
starts with a prodromal stage (stage 1), where mainly negative and affective 
symptoms are present with considerable deterioration in functioning (Figure 2) 
[15]. The second stage is the acute episode of schizophrenia, dominated by positive 
symptoms [15]. The residual or third stage is described by the absence of posi-
tive symptoms and increased presentation of negative symptoms (resembling to 
stage 1) [15]. Finally, the authors differentiate between subchronic (stage 4) and 
chronic (stage 5) phases based on the duration of the illness; if it persists more than 
6 months but less than 2 years then it is stage 4, if it is present for more than 2 years 
then it is stage 5 [15]. Additionally, it is also emphasized that a “rollback phenom-
enon” can also occur where patients in stage 2 progress to stage 1 instead of stage 3 
and achieve remission eventually [15].
2.3 The staging concepts of Lieberman and Insel
According to Lieberman, schizophrenia is composed of three pathophysiologic 
phases described in four stages [11, 16]. The first is the neurodevelopmental or pre-
morbid phase which begins in early adolescence or even sooner and is characterized 
by mild cognitive and social impairments (stage 1) (Figure 3) [16]. Then the second 
phase is the neuroplastic phase which can be further divided into prodromal, and 
onset and deterioration sub-phases and is referred to as stage 2 and 3 in the model, 
Figure 1. 
The Hoffman staging concept.
Figure 2. 
The Fava & Kellner staging concept.
Psychosis - Phenomenology, Psychopathology and Pathophysiology
4
accordingly [16]. Throughout the prodromal stage besides the above mentioned 
deficits, mild psychotic symptoms might be already present which lead to a full-
blown psychosis during the onset (stage 3) [16]. The final pathophysiological phase 
is the neuroprogressive one, which is described as the chronic or residual stage 
characterized by considerable negative and cognitive symptoms as well as further 
psychotic episodes [16]. Lieberman recommends the use of antipsychotic medica-
tion only after the onset of the first psychotic episode [16]. Similarly, to Lieberman, 
9 years later Insel also identified the same stages of schizophrenia albeit with 
slightly different names; pre-symptomatic risk (stage 1), pre-psychotic prodrome 
(stage 2), acute psychosis (stage 3) and chronic illness (stage 4) [17, 18]. In his 
staging concept, he also details the features, diagnosis, disability and intervention at 
each distinct stage [17].
2.4 The Singh staging concept
The staging concept by Singh and colleagues focuses predominantly on the chro-
nology of psychosis onset [19]. Their model beings with the prodrome (stage 1), 
which is further divided into two parts; a period of unease (P1) and a period of 
non-diagnostic symptoms (P2) [19]. Then, the second stage is when the first 
psychotic symptoms appear, which refers to positive symptoms such as delusions 
and hallucinations [19]. Before receiving a definite diagnosis (stage 4), there is an 
intermediate stage where the symptoms build up, and there is already a diagnostic 
impression of schizophrenia (stage 3) [19]. Although this staging concept does not 
describe a complete model of SSD, its detailed description of the beginning of the 
disorder made it worthy of being included in this review (Figure 4).
Figure 3. 
The staging concepts of Lieberman and Insel.
Figure 4. 
The Singh staging concept.
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2.5 The Agius staging concept
The simplest and probably most known concept of schizophrenia staging was 
described by Agius after about a decade of the Lieberman model [12]. Based on his 
research, the development of schizophrenia was divided into three distinct stages; 
the prodrome (stage 1), then the first episode (stage 2) and finally, the chronic 
phase (stage 3) (Figure 5) [12]. Although it was not included in the model as a 
separate stage, Agius also agrees on the fact that there is a premorbid phase before 
the prodrome [12]. It is also emphasized that the treatment of schizophrenia needs 
to be in accordance with the different stages of the disorder in order to achieve the 
desired outcomes [12].
2.6 The McGorry staging concept
One of the most developed and referenced [20–24] staging model of schizo-
phrenia was proposed by McGorry and colleagues [10, 11]. This concept starts with 
stage 0, where the patient has no current symptoms yet, but an increased risk of 
psychotic disorder is present (Figure 6) [10]. Then, stage 1 (mild and moderate 
symptoms) is divided into two substages; 1a with mild and non-specific symptoms 
and 1b with subthreshold or moderate symptoms [10]. The first episode of psychosis 
defined to be at stage 2, followed by the three substages of stage 3 (incomplete remis-
sion and relapse(s)); incomplete remission (3a), relapse of psychotic disorder (3b) 
and multiple relapses (3c) [10]. Finally, stage 4 represents a persistent and severe ill-
ness [10]. Importantly, this staging concept can be applied not only to patients with 
SSD but also to patients with other severe mood disorders such as depression or bipo-
lar disorder [10]. Besides the description of different stages, McGorry and colleagues 
also provided information regarding the potential interventions as well as indicative 
biological and endophenotypic markers to each stage in their framework [10].
Figure 5. 
The Agius staging concept.
Figure 6. 
The McGorry staging concept.
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2.7 The Cosci staging concept
In 2013, Cosci and colleagues – similarly to this book chapter – aimed to summa-
rize and integrate the staging models of schizophrenia, and other major psychiatric 
disorders through a systematic review and came up with a general staging concept 
that is composed of four stages (Figure 7) [11]. The model starts with a prodromal 
phase (stage 1) and follows the basic stages of psychiatric disorders in a longitudinal 
fashion with stage 2 being the acute manifestation, stage 3 the residual phase and 
stage 4 the chronic phase [11]. In contrast to McGorry [10] and Lieberman [16], the 
premorbid or increased risk phase was not included in this concept as they found no 
adequate support from the literature and argued that it has less clinical relevance as 
it can be only appraised retrospectively [11].
2.8 The Fountoulakis staging concept
A novel concept of clinical staging in schizophrenia was proposed by 
Fountoulakis and colleagues in 2019 using the Positive and Negative Syndrome 
Scale (PANSS) and the 5-factor model (a model based on the notion that schizo-
phrenia is characterized by positive, negative, cognitive, affective and hostility 
symptoms) [25]. They aimed to develop a staging concept empirically through 
analyzing a very large sample (n = 2358) of stabilized schizophrenia patients with 
varying ages [25]. Based on the results, they identified 4 major stages of schizo-
phrenia (Figure 8), starting with stage 1, dominated by positive symptoms. Besides 
describing the most influential symptom domain of each stage, they also provided 
a timeline of the disorder. According to this timeline, stage 1 lasts about 3 years on 
average [25]. In this first stage, excitement and hostility symptoms were found to 
increase over time and becoming the leading symptom group of stage 2, that lasts 
Figure 8. 
The Fountoulakis staging concept.
Figure 7. 
The Cosci staging concept.
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about 9 years on average [25]. Throughout the first two stages, negative and depres-
sion/ anxiety symptoms were stable and started to increase steadily around the end 
of stage 2 [25]. Importantly, the second stage was further divided into 2 substages: 
stage 2a and 2b [25]. The latter lasts about 6 years and is described by the rise of 
negative, depressive and cognitive symptoms. During stage 3, which lasted 13 years 
on average, the most dominant symptoms were the depressive ones [25]. In the first 
phase of stage 3 (3a), hostility symptoms were found to decline, while negative 
and cognitive symptoms were increasing [25]. Then, in the second part of stage 3 
(3b), positive and hostility symptoms almost disappeared [25]. Finally, the fourth 
stage was found to be characterized by cognitive symptoms, and according to their 
timeline, it begins 25 years after the first episode on average [25]. Similarly to the 
previous stages, stage 4 is also divided into 4a and 4b substages; 4a lasts about 
15 years on average and is described by the robust increase of negative and cognitive 
symptoms, while 4b starts about 40 years after the first onset and is found to be 
dominated by mainly the neurocognitive deficits that the patients experience [25].
2.9 Similarities and differences between the historical staging concepts
A summary of the reviewed historical staging models of SSD is presented in 
Table 1. Interestingly, only about half of the staging concepts begin with a pre-
morbid phase (Singh starts with prodrome which has a sub-stage, P1, that can be 
regarded as a premorbid phase), and except Fountoulakis and colleagues, all models 
have a prodromal phase. Importantly, the acute and chronic phase is present in all 
models (the Singh staging concept is not counted here, as it focused on the beginning 
of the disorder), while only again about half of the models included a residual or sub-
chronic phase. In terms of the underlying pathophysiological changes of SSD in rela-
tion to the different stages, evidence from brain imaging studies provide support for 
the general notion that abnormalities are more prevalent in later stages than in earlier 
ones, these abnormalities are progressively worsening while patients advance from 
an earlier to a later stage and finally, supportive treatments such as essential fatty 
acid supplementation are more effective in the beginning of the disorder [26, 27]. 
Nonetheless, it is challenging to validate one particular model via pathophysiological 
changes described by brain abnormalities or other biomarkers as there is consider-
able heterogeneity in the clinical and pathophysiological picture of SSDs [27]. For 
instance, the size of the ventricles does not necessarily correlate with the severity or 
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3. The integrated staging model of schizophrenia spectrum disorders
Although the reviewed historical staging concepts of SSD are slightly different 
from one another, they can easily be integrated into one coherent model. To start 
with, there is one clinical stage that is present in all concepts: the first episode of 
psychosis. This acute phase can be interpreted as a milestone that divides the course 
of the disorder into a before and an after phase and so can be set as the first stage of 
the disorder. It is also the stage where the patient is most likely to be recognized and 
treated for the first time.
Most, but not all clinical staging concepts deal with the before phase, officially 
called the prodrome, since it is often determined retrospectively and is highly 
debated from the perspective of treatment [11]. Nonetheless, evidence is emerg-
ing regarding early interventions and it might become more and more relevant 
in the future [28]. Hence, in the integrated staging model, the prodromal phase 
is regarded as stage 0, representing its importance but debated nature. In many 
of the reviewed staging models, prodrome was further divided into substages, 
i.e. increased risk or pre-morbid phase, and mild symptoms or prodromal phase 
[10, 16, 17]. Although these substages might be important in the development of 
SSD, recognizing them may be even more challenging and unnaturalistic in real-
life settings [11, 28, 29]. Thus, in the integrated model, this stage is not subdivided 
further.
Similarly, to the before phase, there are slight differences between the histori-
cal staging concepts in terms of what happens after the first onset of psychotic 
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of symptoms [12, 16, 17] while others define three or even more distinct stages 
[13, 15, 25]. The most influential models opt however for two subsequent stages 
[10, 11, 19]; a residual or pre-chronic stage characterized by incomplete remis-
sion, relapses as well as depressive symptoms, and a chronic stage with persistent 
symptoms dominated by neurocognitive deficits. In the integrated staging model 
these phases represent stage 2 (remission and relapse) and 3 (chronic psychosis), 
respectively (Figure 9).
3.1 The prodrome (stage 0)
In the integrated staging model of SSD, stage 0 is called the prodrome. This is 
a period of the disorder when some mild or even moderate symptoms are pres-
ent, however there is no sign of full-blown psychosis yet [10]. Given the fact that 
this phase is just preceding the first onset of psychotic symptoms, the prodrome 
is a retrospective concept that can be mainly recognized and defined afterwards 
[28, 29]. In terms of timeline, the prodrome can last from weeks to even years, but 
most typically, its duration is about a year [28].
During the prodrome, the patient goes through considerable changes in their 
behavior and might start to experience disturbance in thinking which in turn results 
in anxiety or even anger [13]. The symptoms present during this time are heter-
ogenous; mostly negative symptoms such as anhedonia, asociality or amotivation 
along with changes in perception, mood, beliefs and cognition [29, 30]. In terms of 
neurobiological changes, there are signs of abnormal dopamine synthesis, prefron-
tal cortex (PFC) dysfunctions and gray matter volume reductions in several brain 
regions including the PFC, hippocampal gyrus and lateral temporal lobe [31–34].
Given the notion that the earlier the treatment is received, the better the progno-
sis of SSD, there is considerable interest in starting pharmacological interventions 
during the prodrome [28, 29]. However, the main problem with this concept is the 
potential number of false positives, those individuals who, despite having symp-
toms and distress, will not develop psychosis after the prodromal period [29]. Thus, 
many argue that prescribing antipsychotic medication to these individuals is highly 
questionable from an ethical perspective, claiming that even the newest antipsy-
chotic medications are not without side effects, might induce cognitive harm and 
can stigmatize the patient for life [28, 29, 35].
To overcome the barrier of treating individuals in the prodrome while also 
excluding the false positives, there are tendencies of developing new criteria that 
can accurately detect patients who are in an ‘ultra-high risk’ (UHR) mental state 
and hence are most likely to develop psychosis and benefit from pharmacological 
treatment too [29, 36]. An example of such criteria is the Personal Assessment 
and Crisis Evaluation (PACE), which defines someone at UHR of psychosis if they 
Figure 9. 
The intergraded staging model of schizophrenia spectrum disorders.
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have one or more of the following diagnosis; “(a) attenuated psychotic symptoms, 
(b) brief limited intermittent psychotic symptoms, (c) a significant decrease in 
functioning (maintained for at least a month) with either schizotypal personality 
disorder or a first-degree relative with psychotic disorder” [28, 36, 37].
The aims of early intervention in the UHR group are threefold: first, to alleviate 
the symptoms that the patient experiences; second, to decrease the risk of transi-
tioning to a first episode of psychosis; and third, to reduce the time before starting 
an antipsychotic treatment after the onset of psychosis [36]. To date, there are only 
a few pharmacological trials with antipsychotic medication in this patient group, 
both indicating a tendency for a decreased rate of conversion to psychosis after one 
year [38, 39]. Nonetheless, more research is required to understand the risks and 
benefits of pharmacological treatment during the UHR period. Meanwhile, accord-
ing to current guidelines the use of antipsychotic medication during the prodrome 
is only recommended in case of the more complex cases [40, 41], while the recom-
mended interventions are family psychoeducation, individual or group cognitive 
behavior therapy, active substance use reduction and neuroprotective agents such as 
omega-3 [10].
3.2 The onset (stage 1)
The first stage of the integrated staging model of SSD starts with the acute mani-
festation of psychotic symptoms or in other words the onset of the first episode of 
psychosis. Throughout this stage of the disorder patients experience predominantly 
positive symptoms such as hallucinations, paranoia or delusions and are likely to 
be in denial of accepting that there is something wrong and that they need medical 
help [10, 13]. This denial often manifests in aggression or agitation and might as 
well result in the hospitalization of the patient [42]. Besides the dominating positive 
symptoms, negative symptoms such as alogia or asociality and hostility may also be 
present [16, 25].
Currently, there is no strong scientific evidence on the cut-off point for the 
end of the first episode, nonetheless, it is estimated to be within the first 2–5 years 
following the onset of the psychotic symptoms [43–45]. Indeed, Fountoulakis and 
colleagues found that the first stage of SSD lasts 3 years on average [25].
The main treatment goal during the first stage of SSD is to resolve psychotic 
symptoms and to increase the chances of the patients to returning to their normal 
life as effectively and expeditiously as possible [41]. To do so, antipsychotic medica-
tions are utilized [46], in most cases in the form of oral antipsychotics due to being 
less invasive and more accepted in the long run [47]. Many patients, however, might 
need long-acting, injectable antipsychotics in order to increase compliance [48], as 
several studies indicated that more than 40% of patients are nonadherent during 
the first 9 months of treatment, hence increasing their chance to relapse [49].
In addition to pharmacological treatment it is also important to provide further 
support to the patients and their caregivers via clinical psychologists, occupational 
therapists and social workers [10, 41]. The family or caregivers might need to attend 
psychoeducation or other therapy as well in order to ensure better coping [41].
After the first episode, there are multiple trajectories possible how the disorder 
can continue. According to the thumb rule described by Shepherd and colleagues, 
one third of the patients will go on remission and will not experience any more 
subsequent episode, the second third of the patients will experience one or more 
psychotic episodes (stage 2), while the third group of patients will experience 
multiple relapses and unremitting illness which will be later described as chronic 
disorder (stage 3) [50].
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3.3 Remission and relapse (stage 2)
Between stage 1 and 3 is the most heterogenous phase of the disorder, the 
remission and relapse stage. During this period of SSD, patients first experience a 
temporary or incomplete remission from the first episode, but then there is a relapse 
or even multiple relapses of psychotic symptoms in the form of episodes [10]. If 
looking at the chain of events in a chronological order, before being in remission, 
the patient first responses to the treatment, which is usually determined by a certain 
amount of reduction in symptoms (between 20–50%) on a validated rating scale 
such as the Positive and Negative Syndrome Scale (PANSS) or the Clinical Global 
Impression (CGI) [51, 52]. Then the patient moves to remission, which, according 
to the Remission in Schizophrenia Working Group (RSWG), is an “increasingly 
achievable stage in the treatment of schizophrenia, serving to expand the current 
ceiling of patient progress beyond “stability” [53]. Although there are various crite-
ria on how remission is defined, it essentially means a period of the disorder when 
symptoms are mild and/or there is no “active” psychosis [53]. When symptoms start 
to reappear after this mild or symptom-free period, and the patient is experiencing 
a worsening in functioning, we are talking about relapse [54, 55]. Nonetheless, as 
mentioned previously, a third of patients might not relapse rather achieve recovery 
[50], a state where the patient is able to function both socially and occupationally 
and has considerable symptomatic improvement [55, 56].
The second stage of SSD is hence quite various in terms of the type and severity 
of symptoms. Nonetheless, in most cases, the negative and depressive / anxiety-like 
symptoms [25] are highly dominant in-between relapses, affecting the patient’s 
quality of life enormously [57]. Throughout a relapse the positive and hostility-
related symptoms might particularly increase [25, 55].
According to Fountoulakis and colleagues, the duration of this second phase 
is around 9 years on average, followed by a 13 years-long period dominated by 
depressive symptoms [25], so an up to 10-year long period for the second stage is 
adapted.
The primary treatment goal during this stage is first to achieve complete 
remission and then to prevent relapse as well as to stabilize the patient mediated 
by specialist care services [10]. Given the high level of negative and depressive/ 
anxiety-like symptoms, the secondary aim should be to alleviate these, either by 
using a novel second-generation antipsychotic medication such as cariprazine 
and amisulpride or a combination of antipsychotic and antidepressant 
medication [58].
3.4 Chronic psychosis (stage 3)
The third and final stage of the integrated staging model is the chronic psychosis 
stage. Throughout this period of the SSD the symptoms are still severe, persistent 
or unremitting [12]. The patients might continue to experience numerous relapses 
while usually suffering mostly from negative, affective (depressive/ anxiety-like) 
and neurocognitive symptoms, with the latter increasingly becoming the most 
prominent symptom group of the disorder over time [12, 25]. Suicidal ideation 
might also be more common at this stage of the illness [59]. Nonetheless, patients 
usually develop some kind of acceptance and integrate the fact of the disorder into 
their life [13].
The chronic psychosis stage of SSD begins about 15–20 years after the first 
episode [25, 45]. Patients in this late stage are usually disabled at a certain degree 
and are likely to be unemployed or retired [45].
Psychosis - Phenomenology, Psychopathology and Pathophysiology
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Treatment in the chronic disorder stage is similar to stage 2 treatment with a 
high emphasis on the prevention of further exacerbation of the illness and long-
term stabilization alongside with augmentation strategies and other psychosocial 
therapies such as active social participation and/or vocational rehabilitation 
[10]. Preferred pharmacological treatments include clozapine and long-acting 
antipsychotic medications [12], although drugs addressing negative and cognitive 
 symptoms (such as cariprazine and amisulpride) may also be of benefit [58].
3.5 Summary of the integrated staging model
The integrated staging model starts with the prodrome (stage 0), which is a 
period of the SSD where patients are already experiencing some changes in their 
behavior alongside mild negative and affective symptoms (Figure 10). Diagnosis 
is usually not yet received as the symptoms are too mild and unspecific to be 
certain about what causes them. This period can last from a few weeks to years. 
Pharmacological interventions throughout the prodrome are still researched, 
nonetheless psychosocial therapies are thought to be beneficial.
The first stage of the SSD according to the integrated staging model is the 
onset of the first episode of psychosis characterized by positive and hostility-like 
symptoms. This period can last between 2 and 5 years in average. Regarding treat-
ment, the emphasis is on alleviating mostly positive symptoms and stabilizing the 
patient.
The second stage is the remission and relapse stage which is the most heterog-
enous phase of the disorder. Throughout this period some patients might experience 
one or multiple relapses, however about a third of the patients will stay in remission 
and may go to recovery. The dominating symptoms in-between episodes are the 
negative and affective ones. The remission and relapse stage last about ten years, 
between the 5th and 15-20th year of the illness. The primary goal of treatment 
during this stage is the prevention of relapses and achieving complete remission and 
recovery.
The final stage of SSD is the chronic psychosis stage dominated by increasing 
neurocognitive symptoms. Patients arriving to this late stage are likely to be suffer-
ing from disability and unemployment. Alongside the pharmacological treatments 
that aim to prevent the further exacerbation of illness there is an emphasis on 
psychosocial therapies to increase the everyday functioning of patients.
Figure 10. 
The integrated staging model of schizophrenia spectrum disorders with timeline and symptom domains.
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4. Conclusion
Clinical staging is a more refined form of diagnosis that provides information 
on how an illness progresses and where the patient lies within this progression [10]. 
It is based on the assumption that each stage can be described by a typical clinical 
profile with later stages being associated with greater symptom severity and that 
treating patients in the early stages of the disorder is more efficient [12]. The pri-
mary aim of introducing clinical staging into the field of psychiatry was to promote 
remission and recovery in the early stages of psychiatric disorders and hence to 
prevent patients to progress to later stages [10].
Since 1982, several staging concepts describing the course of psychiatric disor-
ders have emerged. In this systematic review, we have identified and summarized 
9 concepts that outline the clinical staging of schizophrenia spectrum disorders. 
Although there were some variations between the models, all identified the first 
episode of psychosis as a distinct stage that divides the course of the disorder into 
a before and after phase. Most of the variations in the concepts were due to the 
fact that there were disagreements in the number of stages before and after the 
first onset.
In order to unify the described concepts an integrated staging model of schizo-
phrenia spectrum disorder has emerged that describes the course of SSD in four 
stages; the prodrome (stage 0), the onset (stage 1), remission and relapse (stage 
2) and chronic psychosis (stage 3). The integrated model also provides timeline 
around when patients are likely to enter the next stage as well as what symptoms 
dominate and how to best treat them. Nonetheless, it is also important to note that 
not all patients will go through all stages and the primary goal of any treatment is to 
prevent patients to enter a later stage.
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